3 October 2020
Nivolumab and Ipilimumab Approved as Immunotherapy Treatments in the USA
On 2 October 2020, the American Food & Drug Administration approved a combination of nivolumab (OPDIVO, Bristol-Myers Squibb Co) and ipilimumab (YERVOY, Bristol-Myers Squibb Co) as a first-line treatment for adults with unresectable mesothelioma. Randomised open-label trials suggest an improvement in overall survival in the order of approximately 25% when compared with chemotherapy.
The full announcement is available here.
As yet, the treatment is not approved for use in the UK.
Share this blog
Ropewalk Chambers has, over many decades, established a market-leading reputation for detailed and specialist expertise in the field of Industrial Disease litigation.
Whether asbestos, noise, dust, vibration, stress or any other insidious process, including those which are newly emerging, its members have consistently appeared in the leading cases, determining the limits of liability, causation and quantum at first instance and appellate level.
Work is distributed within Chambers to enable Members of Chambers to represent both Claimants and Defendants in this field.
To find out more about our Disease barristers, click here.
Search blog by title or barrister
Subscribe for blog updates
Search by keyword
- Air Pollution
- Bladder Cancer
- Breach of Duty
- Contributory Negligence
- Dupuytren's Contracture
- Dust Diseases
- Expert Evidence
- Fatal Accidents
- Noise-Induced Hearing Loss
- Restoration of Companies
- (In)divisible, That's What You Are
- Dementia in Sports Participants: An Industrial Disease?
- The Scope and Limits of Acceptable Risk in Exposure Cases